BPP 0.00% 2.8¢ babylon pump & power limited

announcement out

  1. 403 Posts.
    lightbulb Created with Sketch. 14
    ASX Announcement
    09 November 2007

    IM Medical’s Intelliheart testing system is being introduced to the health system in Italy
    with an agreement for a pilot program at a major hospital in the province of Umbria.
    The Italian agreement represents the first expansion of Intelliheart into the international
    marketplace. It provides for hundreds of tests to be done over a period of two months in a
    leading public hospital under the supervision of a prominent Italian cardiologist.
    Data including ECGs will be transmitted online back to Melbourne for analysis, using
    Intelliheart’s unique software system.
    The program is being carried out at the Azienda Sanitaria Locale 1 Umbria (Hospital of
    Citta Castello). It will be supervised by Dr Maurizio Cocchieri, Director of Cardiology.
    The Chief Executive Officer of IM Medical Limited, Mr Tommas Bonvino, said: “The
    Italian agreement is a milestone for the company. It proves there is great interest in our
    technology in the big markets and gives the company great confidence as it rolls out its’
    international marketing program.”
    Mr Bonvino said the Umbrian program placed IM Medical in a good position to introduce
    Intelliheart to other parts of the Italian health system and the wider EU market.
    IM Medical Limited has been negotiating with providers and suppliers in several countries
    since Intelliheart was boosted with the first stage of the integration of the Cardanal
    technology in September and receipt of TGA and CE approvals.
    Mr Bonvino said, in the European region, active discussions were under way in
    Switzerland, Germany and other parts of Italy.
    Intelliheart uses a series of tests to assess cardiac risk. The unique Cardanal technology,
    acquired by IM Medical early this year, provides cardiologists with more sensitive and
    reliable tools.
    Cardanal is being introduced in two stages.
    The first stage, added to Intelliheart tests in September, allows doctors to analyse the
    heart’s electrical activity over a considerably longer period and enables a much fuller
    picture than the standard snapshot provided by a conventional electrocardiogram (ECG).
    Cardanal also allows real-time internet transmission and storage of the ECG signals,
    paving the way for remote diagnosis of heart problems.
    The second stage involves the Cardanal Predictive Index (CPI), which provides a simple
    and improved prediction system for heart problems based on Intelliheart data. The CPI will
    be introduced and marketed after peer-reviewed studies are published in the international
    medical journals.
    Enquiries : Tommas Bonvino, CEO (03) 9860 0999
watchlist Created with Sketch. Add BPP (ASX) to my watchlist
(20min delay)
Mkt cap ! $23.44M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
4 581501 2.7¢

Sellers (Offers)

Price($) Vol. No.
2.9¢ 72186 2
View Market Depth
Last trade - 16.12pm 28/09/2020 (20 minute delay) ?
BPP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.